Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$37.35M$37.35M+42.4% vs Q2 2019 Net Income-$90.48M-$90.48MN/M vs Q2 2019 EPS Diluted-$1.31-$1.31N/M vs Q2 2019 Operating Income-$90,196,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$72,030,000N/M Margins · derivedOperating margin-241.5%+192.7 pt vs Q2 2019
Net margin-242.3%+176.8 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 30, 2020 · 30 d after period end